Jump to content

Messoud Ashina

From Wikipedia, the free encyclopedia
Messoud Ashina
Born(1965-12-29)29 December 1965
Baku, Azerbaijan
EducationUniversity of Copenhagen, Azerbaijan Medical University
Medical career
ProfessionNeurologist
InstitutionsUniversity of Copenhagen; Rigshospitalet
AwardsRoche Prize for Scientific Achievements in Neurology,
GlaxoSmithKline Research Prize,
Mogens Fog Prize,
Monrad-Krohns Prize
TÜBA Academy Prize
KFJ Prize

Messoud Ashina (born December 29, 1965) is a Danish-Azerbaijani neurologist and neuroscientist.[1][2] He is currently Professor of Neurology at the University of Copenhagen and Senior Consultant of Neurology at Copenhagen University Hospital - Rigshospitalet. He leads the Human Migraine Research Unit at the Danish Headache Center, Copenhagen University Hospital - Rigshospitalet.[1] Ashina is also Director of the Danish Knowledge Center on Headache Disorders and Past President of the International Headache Society.[3][4] As of 2024, Ashina is ranked as the world's leading expert on headache disorders by Expertscape.[5]

Education

[edit]

Ashina earned his medical degree at the age 22 from Azerbaijan Medical University in 1988.[1][6] He later received his PhD and D.M.Sc. degrees at University of Copenhagen and completed his residency in neurology at Copenhagen University Hospitalet - Rigshospitalet.[1]

Personal life

[edit]

Messoud Ashina was born on December 29, 1965, in Baku, Azerbaijan.[6] His father, Rustam Ashina was an architect, while his mother, Nelli Hajiyeva, is a retired biologist.[1]

He lives in Copenhagen and is married to Camilla Ashina who is a dentist.[6] They have two children.

Research

[edit]

Ashina is an acclaimed neuroscientist and considered one of the most prolific contributors to headache sciences.[5] His academic works focus on migraine,[7] which is a ubiquitous neurological disorder that affects more than one billion people worldwide.[8] Ashina and his research lab have been key figures in the development and refinement of human provocation models that can be used to map signaling pathways underlying migraine pathogenesis and to identify novel drug targets.[7][9][10] In these provocation models, endogenous signaling molecules or other hypothesized 'trigger' agents are used to induce migraine attacks in people with migraine, whereas healthy volunteers most often develop no more than a mild headache.[7]

In his early work, Ashina and colleagues discovered that intravenous infusion of pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) induced migraine attacks in people with migraine.[11] He then showed that PACAP infusion caused migraine attacks accompanied by a long-lasting dilation of cranial blood vessels.[12] This contrasted findings using the closely related vasoactive intestinal polypeptide (VIP), which elicited mild headache (but not migraine) and only a short-lasting vasodilation.[12] Upon extending the infusion duration of VIP, Ashina discovered that VIP now induced migraine attacks accompanied by long-lasting vasodilation.[13] This led to the hypothesis that prolonged dilation of cranial arteries might contribute to the pathogenesis of migraine and other headache disorders.[14] Of note, promising phase II trial results have been announced on the effectiveness of a PACAP-targeted drug for migraine prevention.[15]

Ashina has, in addition to PACAP and VIP, identified other peptidergic drug targets for migraine and related headache disorders. These include adrenomedullin, amylin, and specific prostaglandins; all of which have been shown to induce migraine attacks in people with migraine.[16][17][18][19] Efforts are ongoing for developing novel drugs directed against the signaling of these migraine-inducing peptides.

Ashina has also posited that accumulation of intracellular cyclic adenosine monophosphate (cAMP) must play an important role in migraine pathogenesis because the intracellular effects of PACAP receptor-binding are mediated by cAMP-dependent signaling pathways.[11] This was confirmed by Ashina's lab when oral administration of cilostazol - a blocker of cAMP degradation - induced migraine attacks in people with migraine without aura.[20] Ashina later hypothesized that downstream effects of cAMP-mediated migraine attacks were likely to involve opening of potassium channels.[7] This hypothesis has been supported by experimental data from provocation studies, in which Ashina and colleagues demonstrated that openers of adenosine-triphosphate (ATP)-sensitive potassium channels and large conductance calcium-activated potassium channels induced migraine attacks in people with migraine without aura.[9][21][22] Furthermore, Ashina and colleagues have also found that intravenous infusion of an ATP-sensitive potassium channel opener appears to be a potent inducer of migraine attacks with aura in people with migraine with aura.[23]

Publications

[edit]

Ashina has authored over 450 papers, abstracts and book chapters, including more than 400 registered publications in PubMed (1997-2024).[24] He is the editor of the book 'Pathophysiology of Headaches'. His overall citation index is 20,142 (13,278 since 2018), and he has an H-index of 82 (65 since 2019).[25]

References

[edit]
  1. ^ a b c d e "Messoud Ashina". www.rigshospitalet.dk. Retrieved 2021-05-19.
  2. ^ "Messoud Ashina". The Lancet Neurology. 12 (5): 432. 2013-05-01. doi:10.1016/S1474-4422(13)70097-8. ISSN 1474-4422. S2CID 54299949.
  3. ^ "videnscenterforhovedpine.dk" (in Danish). Retrieved 2021-05-19.
  4. ^ "Meet the President". International Headache Society. Retrieved 2021-05-19.
  5. ^ a b "Headache: Worldwide - Expertscape.com". expertscape.com. Retrieved 2021-05-19.
  6. ^ a b c Bundgaard, Bente (2021-04-29). "Fra Kaukasus til København". Dagens Medicin (in Danish). Retrieved 2021-05-19.
  7. ^ a b c d Ashina, Messoud (2020-11-04). "Migraine". New England Journal of Medicine. 383 (19): 1866–1876. doi:10.1056/NEJMra1915327. PMID 33211930. S2CID 227078662.
  8. ^ Ashina, Messoud; Katsarava, Zaza; Do, Thien Phu; Buse, Dawn C.; Pozo-Rosich, Patricia; Özge, Aynur; Krymchantowski, Abouch V.; Lebedeva, Elena R.; Ravishankar, Krishnamurthy; Yu, Shengyuan; Sacco, Simona (2021-04-17). "Migraine: epidemiology and systems of care". The Lancet. 397 (10283): 1485–1495. doi:10.1016/S0140-6736(20)32160-7. ISSN 0140-6736. PMID 33773613. S2CID 232359483.
  9. ^ a b Ashina, Messoud; Terwindt, Gisela M.; Al-Karagholi, Mohammad Al-Mahdi; Boer, Irene de; Lee, Mi Ji; Hay, Debbie L.; Schulte, Laura H.; Hadjikhani, Nouchine; Sinclair, Alexandra J.; Ashina, Håkan; Schwedt, Todd J. (2021-04-17). "Migraine: disease characterisation, biomarkers, and precision medicine". The Lancet. 397 (10283): 1496–1504. doi:10.1016/S0140-6736(20)32162-0. hdl:1887/3276377. ISSN 0140-6736. PMID 33773610. S2CID 232359490.
  10. ^ Ashina, Messoud; Hansen, Jakob Møller; á Dunga, Bára Oladóttir; Olesen, Jes (December 2017). "Human models of migraine — short-term pain for long-term gain". Nature Reviews Neurology. 13 (12): 713–724. doi:10.1038/nrneurol.2017.137. ISSN 1759-4766. PMID 28984313. S2CID 7546339.
  11. ^ a b Schytz, Henrik Winther; Birk, Steffen; Wienecke, Troels; Kruuse, Christina; Olesen, Jes; Ashina, Messoud (January 2009). "PACAP38 induces migraine-like attacks in patients with migraine without aura". Brain. 132 (1): 16–25. doi:10.1093/brain/awn307. ISSN 1460-2156. PMID 19052139.
  12. ^ a b Amin, Faisal Mohammad; Hougaard, Anders; Schytz, Henrik W.; Asghar, Mohammad S.; Lundholm, Elisabet; Parvaiz, Arushma I.; de Koning, Patrick J. H.; Andersen, Malene R.; Larsson, Henrik B. W.; Fahrenkrug, Jan; Olesen, Jes; Ashina, Messoud (March 2014). "Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38". Brain. 137 (3): 779–794. doi:10.1093/brain/awt369. ISSN 1460-2156. PMID 24501094.
  13. ^ Pellesi, Lanfranco; Al-Karagholi, Mohammad Al-Mahdi; De Icco, Roberto; Coskun, Hande; Elbahi, Fatima Azzahra; Lopez-Lopez, Cristina; Snellman, Josefin; Hannibal, Jens; Amin, Faisal Mohammad; Ashina, Messoud (2021-08-06). "Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial". JAMA Network Open. 4 (8): e2118543. doi:10.1001/jamanetworkopen.2021.18543. ISSN 2574-3805. PMC 8346940. PMID 34357396.
  14. ^ Ashina, Messoud (2020-11-05). Ropper, Allan H. (ed.). "Migraine". New England Journal of Medicine. 383 (19): 1866–1876. doi:10.1056/NEJMra1915327. ISSN 0028-4793. PMID 33211930. S2CID 227078662.
  15. ^ "Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention". News Powered by Cision. 2023-04-19. Retrieved 2024-02-21.
  16. ^ Ghanizada, Hashmat; Al-Mahdi Al-Karagholi, Mohammad; Arngrim, Nanna; Mørch-Rasmussen, Mette; Walker, Christopher S.; Hay, Debbie L.; Ashina, Messoud (2021-05-18). "Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine: A Randomized Crossover Study". Neurology. 96 (20): e2488 – e2499. doi:10.1212/WNL.0000000000011930. ISSN 0028-3878. PMID 33827963. S2CID 233183405.
  17. ^ Ghanizada, Hashmat; Al-Karagholi, Mohammad Al-Mahdi; Walker, Christopher S.; Arngrim, Nanna; Rees, Tayla; Petersen, Jakeb; Siow, Andrew; Mørch-Rasmussen, Mette; Tan, Sheryl; O'Carroll, Simon J.; Harris, Paul; Skovgaard, Lene Theil; Jørgensen, Niklas Rye; Brimble, Margaret; Waite, Jayme S. (June 2021). "Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients". Annals of Neurology. 89 (6): 1157–1171. doi:10.1002/ana.26072. ISSN 0364-5134. PMC 8486152. PMID 33772845.
  18. ^ Wienecke, T; Olesen, J; Ashina, M (February 2010). "Prostaglandin I 2 (epoprostenol) triggers migraine-like attacks in migraineurs". Cephalalgia. 30 (2): 179–190. doi:10.1111/j.1468-2982.2009.01923.x. ISSN 0333-1024. PMID 19614689. S2CID 10838594.
  19. ^ Antonova, Maria; Wienecke, Troels; Olesen, Jes; Ashina, Messoud (August 2012). "Prostaglandin E 2 induces immediate migraine-like attack in migraine patients without aura". Cephalalgia. 32 (11): 822–833. doi:10.1177/0333102412451360. ISSN 0333-1024. PMID 22718556.
  20. ^ Guo, Song; Olesen, Jes; Ashina, Messoud (November 2014). "Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase". Brain. 137 (11): 2951–2959. doi:10.1093/brain/awu244. ISSN 1460-2156. PMID 25161294.
  21. ^ Al-Karagholi, Mohammad Al-Mahdi; Hansen, Jakob Møller; Guo, Song; Olesen, Jes; Ashina, Messoud (2019-09-01). "Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine". Brain. 142 (9): 2644–2654. doi:10.1093/brain/awz199. ISSN 0006-8950. PMID 31292608.
  22. ^ Al-Mahdi Al-Karagholi, Mohammad; Ghanizada, Hashmat; Waldorff Nielsen, Cherie Amalie; Skandarioon, Camilla; Snellman, Josefin; Lopez-Lopez, Cristina; Hansen, Jakob Møller; Ashina, Messoud (2021-02-17). "Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine". Pain. 162 (10): 2512–2520. doi:10.1097/j.pain.0000000000002238. ISSN 0304-3959. PMID 34252916. S2CID 233954463.
  23. ^ Al-Karagholi, Mohammad Al-Mahdi; Ghanizada, Hashmat; Nielsen, Cherie Amalie Waldorff; Hougaard, Anders; Ashina, Messoud (2021-03-26). "Opening of ATP sensitive potassium channels causes migraine attacks with aura". Brain. 144 (8): 2322–2332. doi:10.1093/brain/awab136. ISSN 0006-8950. PMID 33768245.
  24. ^ "PubMed.com - Messoud Ashina".
  25. ^ "Google Scholar - Messoud Ashina".
Retrieved from "https://wiki.riteme.site/w/index.php?title=Messoud_Ashina&oldid=1209331215"